Latest news with #ImportantProjectofCommonEuropeanInterest
Yahoo
6 days ago
- Business
- Yahoo
FineHeart Named Leader of the IPCEI Health Tech4Cure to Spearhead the Structuring of the European Implantable Medical Device Sector
BORDEAUX, France, July 24, 2025--(BUSINESS WIRE)--FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, has been designated as the lead partner of the IPCEI Tech4Cure (Important Project of Common European Interest), dedicated to the implantable medical device (IMD) sector. This project is jointly notified by six EU Member States – France, Hungary, Italy, Latvia, Slovakia, and Slovenia FineHeart will carry out its SmartDMIA program to structure the innovative active implantable medical device (AIMD) sector, which is essential for public health and Europe's industrial autonomy, in synergy with other European laureates of the Tech4Cure program. Arnaud Mascarell, CEO and co-founder of FineHeart, said: "Being named leader of the IPCEI Tech4Cure with our SmartDMIA project is a source of immense pride. It is the recognition of our innovation ability and our technological and industrial leadership. This project will strengthen our sustainable growth and increase our international visibility. Together with our academic and industrial partners, we will build a sovereign, competitive and sustainable AIMD industry serving the health of European citizens." The SmartDMIA project will cover the entire value chain—from design to industrialization—of next-generation active implantable medical devices (AIMDs), for which energy supply is a major technological and medical challenge. The main development areas are: Extending the lifespan of encapsulated electronic components, enabling the integration of miniaturized transcutaneous energy and data transfer systems Developing universal interoperability between devices, regardless of their power (from a few milliwatts to 30 W), to optimize energy management and diagnostics and promote personalized medicine (5P medicine) Harmonization of standards for communication, cybersecurity, and interconnection with hospital systems and digital platforms. FineHeart will leverage its R&D know-how perfected during the development of FlowMaker®, the world's first and only miniaturized, fully implantable, wireless cardiac flow accelerator with no external battery for the treatment of advanced heart failure. This breakthrough device, currently in European clinical trials, adapts to the progression of the disease and provides physiological support synchronized with the heart's natural contractions. Through this pioneering role, FineHeart has become a strategic player in the transformation of the European AIMD sector, contributing its expertise and supporting European industrial competitiveness. About the PIIEC Launched by France in 2022, the PIIEC Santé aims to create a "Europe of Health" by promoting the emergence of European champions in disruptive technologies in the sector. This initiative aims to strengthen European production capacities in the health field, while stimulating the formation of ambitious European partnerships around innovative projects, thus ensuring European sovereignty. Coordinated by the Directorate-General for Enterprise (DGE), this project is being rolled out in two complementary waves: the first, authorized on May 28, 2024, targets essential medicines and critical molecules (Med4Cure); the second, entitled Tech4Cure, is dedicated to innovative MedTech medical devices (Tech4Cure). Tech4Cure aims to establish projects at European level focusing on: The lifespan of active implantable medical devices, in particular the lifespan of batteries and any components, materials, and technologies designed to extend the lifespan of active implantable medical devices, thereby promoting the digital and ecological transition. Connected and portable medical imaging solutions to promote more compact imaging devices, harnessing the potential of AI and IoT to facilitate remote examinations and increase the pool of available equipment. Sustainable design of medical devices, by strengthening the ecological transition in the design of medical devices, in particular through the use of biomaterials and eco-design to stimulate innovation in raw material supply and sustainability. About FineHeart - FineHeart View source version on Contacts Media RelationsAnnie-Florence Loyerafloyer@ +33 (6) 88 20 35 59 FineHeart Communications James +33 (0) 7 60 92 77 72 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
6 days ago
- Business
- Business Wire
FineHeart Named Leader of the IPCEI Health Tech4Cure to Spearhead the Structuring of the European Implantable Medical Device Sector
BORDEAUX, France--(BUSINESS WIRE)--FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, has been designated as the lead partner of the IPCEI Tech4Cure (Important Project of Common European Interest), dedicated to the implantable medical device (IMD) sector. This project is jointly notified by six EU Member States – France, Hungary, Italy, Latvia, Slovakia, and Slovenia FineHeart will carry out its SmartDMIA program to structure the innovative active implantable medical device (AIMD) sector, which is essential for public health and Europe's industrial autonomy, in synergy with other European laureates of the Tech4Cure program. Arnaud Mascarell, CEO and co-founder of FineHeart, said: " Being named leader of the IPCEI Tech4Cure with our SmartDMIA project is a source of immense pride. It is the recognition of our innovation ability and our technological and industrial leadership. This project will strengthen our sustainable growth and increase our international visibility. Together with our academic and industrial partners, we will build a sovereign, competitive and sustainable AIMD industry serving the health of European citizens." The Smart DMIA project will cover the entire value chain—from design to industrialization—of next-generation active implantable medical devices (AIMDs), for which energy supply is a major technological and medical challenge. The main development areas are: Extending the lifespan of encapsulated electronic components, enabling the integration of miniaturized transcutaneous energy and data transfer systems Developing universal interoperability between devices, regardless of their power (from a few milliwatts to 30 W), to optimize energy management and diagnostics and promote personalized medicine (5P medicine) Harmonization of standards for communication, cybersecurity, and interconnection with hospital systems and digital platforms. FineHeart will leverage its R&D know-how perfected during the development of FlowMaker®, the world's first and only miniaturized, fully implantable, wireless cardiac flow accelerator with no external battery for the treatment of advanced heart failure. This breakthrough device, currently in European clinical trials, adapts to the progression of the disease and provides physiological support synchronized with the heart's natural contractions. Through this pioneering role, FineHeart has become a strategic player in the transformation of the European AIMD sector, contributing its expertise and supporting European industrial competitiveness. About the PIIEC Launched by France in 2022, the PIIEC Santé aims to create a "Europe of Health" by promoting the emergence of European champions in disruptive technologies in the sector. This initiative aims to strengthen European production capacities in the health field, while stimulating the formation of ambitious European partnerships around innovative projects, thus ensuring European sovereignty. Coordinated by the Directorate-General for Enterprise (DGE), this project is being rolled out in two complementary waves: the first, authorized on May 28, 2024, targets essential medicines and critical molecules (Med4Cure); the second, entitled Tech4Cure, is dedicated to innovative MedTech medical devices (Tech4Cure). Tech4Cure aims to establish projects at European level focusing on: The lifespan of active implantable medical devices, in particular the lifespan of batteries and any components, materials, and technologies designed to extend the lifespan of active implantable medical devices, thereby promoting the digital and ecological transition. Connected and portable medical imaging solutions to promote more compact imaging devices, harnessing the potential of AI and IoT to facilitate remote examinations and increase the pool of available equipment. Sustainable design of medical devices, by strengthening the ecological transition in the design of medical devices, in particular through the use of biomaterials and eco-design to stimulate innovation in raw material supply and sustainability. About FineHeart - FineHeart
Yahoo
16-04-2025
- Business
- Yahoo
NEUMAN & ESSER Receives Order for Hydrogen Storage Project in Northern Germany
The energy service provider EWE is driving forward the conversion of its gas storage site in Wesermarsch for the storage of hydrogen. NEUMAN & ESSER will supply EWE with two four-crank, horizontal piston compressors size 320 as part of the major four-part 'Clean Hydrogen Coastline' project. These compressors form a central component for future large-scale hydrogen storage in a converted natural gas cavern. EWE aims to store hydrogen in this from 2027. From that time, the green gas will be available when it is needed, not when it is produced. Large-scale hydrogen storage will thus improve the secure and flexible supply of future hydrogen users. The project is an essential step towards integrating green hydrogen technology into the existing energy infrastructure and a key project for the energy transition. NEUMAN & ESSER and EWE are thus jointly making a significant contribution to the security of supply and the ramp-up of a hydrogen economy. 'We are very pleased that we can make a decisive contribution to the development of the green hydrogen economy in Germany by supplying the centerpiece of the hydrogen storage facility,' says Jens Wulff, Managing Director of NEUMAN & ESSER Deutschland, 'and that the funding commitments made by the German government and the state of Lower Saxony last summer for the EWE 'Clean Hydrogen Coastline' project have paved the way for strategically important projects such as this one. The signing of the contract with EWE shows our determination to realize these major projects quickly.' EWE is converting one of seven underground natural gas caverns at its cavern site in Huntorf in the Wesermarsch region for the storage of hydrogen. The Huntorf project is part of the large-scale 'Clean Hydrogen Coastline' project. This brings together the production, storage, transportation, and use of green hydrogen, and thus implements the political requirements. EWE received the funding approval for the four-part large-scale project as part of the European IPCEI program (Important Project of Common European Interest) in summer 2024. EWE is currently in the detailed planning phase and intends to store and release hydrogen in the next two to three years. The awarding of the compressors to NEUMAN & ESSER is a decisive milestone in the realization of the project. The family business was chosen for its extensive experience and technical expertise. The compressors play a central role in storing and releasing hydrogen from the cavern, ensuring maximum safety and efficiency. EWE has proven that hydrogen can be stored safely in salt caverns in a pilot project at its gas storage site in Rüdersdorf near Berlin. EWE is now applying the knowledge gained from the construction and operation of the 500 cubic meter test cavern to caverns with a volume 1,000 times larger, such as the one in Wesermarsch. 'Our aim is to establish large-scale caverns for hydrogen storage. With 37 salt caverns, EWE alone has 15 percent of all German cavern storage facilities that are suitable for storing hydrogen,' says Peter Schmidt, Managing Director of EWE GASSPEICHER. About NEUMAN & ESSER At NEUMAN & ESSER the long experience with gas compression and mechanical processing solutions builds the foundation for technologies required for a decarbonized society. We are spearheading the energy transition and the circular economy with integrated solutions as an OEM for: piston and diaphragm compressors, electrolyzers and reformer technologies, grinding and classifying plants. Family-owned for almost 200 years, today more than 1,500 employees are committed to bringing challenging projects to life around the world – from evaluating project feasibility, through engineering, construction, and commissioning to digitally supported 360° service during operation. NEUMAN & ESSER is the partner of the industry for a future with energy from renewable sources and sustainable raw materials. Further information on NEUMAN & ESSER solutions can be found at About EWE As an innovative service provider, EWE is active in the business areas of energy, telecommunications and information technology. With over 10,800 employees and a turnover of ten billion euros in 2023, EWE is one of the largest energy companies in Germany. Headquartered in Oldenburg, Lower Saxony, the company is predominantly in municipal hands. It supplies around 1.4 million customers in northwest Germany, Brandenburg and Rügen with electricity, 0.7 million with natural gas and 0.7 million with telecommunications services. EWE plays a pioneering role in the areas of security of supply, climate protection and digital participation. To this end, the Group is investing in the expansion of the electricity grids, the expansion of the optical fiber infrastructure, the construction of new wind turbines and is a leader in the expansion of the hydrogen infrastructure in the coming years. Find out more about EWE at
